News Related to Open Angle Glaucoma

Related coverage linked through entity extraction aliases.

Nicox Receives Positive FDA Feedback for NCX 470 Glaucoma Treatment Ahead of NDA Submission

Feb 16, 2026

Nicox SA received positive written feedback from a pre-NDA meeting with the FDA for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma. The NDA submission remains on track for summer 2026.

Ocular Therapeutix Reports Positive Phase 3 SOL-1 Trial Results for AXPAXLI in Wet AMD

Feb 14, 2026

Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.